Adaptive Biotech CEO sells 600K shares after option exercise
Adaptive Biotechnologies Corp (ADPT) reported insider transactions by CEO and Chairman Chad M. Robins involving an exercise-and-sell pattern over two days.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp (ADPT) reported insider transactions by CEO and Chairman Chad M. Robins involving an exercise-and-sell pattern over two days. On August 17 and 18, 2026, Robins exercised stock options for a total of 600,000 shares of common stock at an exercise price of $6.55 per share. He then sold 600,000 shares of common stock in multiple open-market transactions at weighted average prices around $24–$26 per share, as described in the price-range footnotes. The options exercised were fully vested and would have expired on February 7, 2028.
Insider Trade Summary
Exercise and Sale: 600,000 shares ($10.95M approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
ROBINS CHAD M
Role
CEO and Chairman
Sold
600,000 shs ($14.88M)
Approx. gross sale proceeds
$14.88M
Approx. exercise cost
$3.93M
Approx. pre-tax spread
$10.95M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F5 | 278,676 | $0.00 | $0.00 |
| Exercise | Common Stock | 278,676 | $6.55 | $1.83M |
| Sale | Common Stock F3 | 278,472 | $24.48 | $6.82M |
| Sale | Common Stock F4 | 204 | $25.14 | $5K |
| Exercise | Stock Option (right to buy) F5 | 321,324 | $0.00 | $0.00 |
| Exercise | Common Stock | 321,324 | $6.55 | $2.10M |
| Sale | Common Stock F1 | 318,799 | $25.08 | $8.00M |
| Sale | Common Stock F2 | 2,525 | $25.57 | $65K |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 2,180,518 shares (Direct)
Footnotes (5)
- F1. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The option was fully vested and exercisable and would have expired on February 7, 2028.
Key Figures
Options exercised: 600,000 shares
Shares sold: 600,000 shares
Option exercise price: $6.55 per share
+3 more
6 metrics
Options exercised
600,000 shares
Total stock options exercised into common stock on August 17–18, 2026
Shares sold
600,000 shares
Total common shares sold in open-market transactions on August 17–18, 2026
Option exercise price
$6.55 per share
Exercise price for stock options converted into common stock
Sale price (weighted average example)
$25.08 per share
Weighted average price for a 318,799-share sale on August 17, 2026
Sale price range (F1)
$24.51–$25.50 per share
Price range for multiple aggregated sales referenced in footnote F1
Option expiration date
February 7, 2028
Expiration date of the fully vested options that were exercised
Key Terms
Stock Option (right to buy), derivative security, weighted average price
3 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ADPT CEO Chad M. Robins report in this Form 4?
Chad M. Robins reported exercising 600,000 stock options at $6.55 and selling 600,000 common shares in open-market transactions on August 17–18, 2026, reflecting an exercise-and-sell sequence.
What options did the ADPT CEO exercise in this Form 4?
He exercised stock options covering 600,000 shares of Adaptive Biotechnologies common stock at an exercise price of $6.55 per share. The options were fully vested and otherwise scheduled to expire on February 7, 2028.
Were the ADPT CEO’s reported sales single trades or multiple transactions?
The reported sales were multiple transactions aggregated as weighted average prices. Footnotes state shares were sold in numerous trades within price ranges such as $24.12–$25.12 and $25.52–$25.64, with full trade breakdowns available on request.
Did this ADPT Form 4 indicate use of a Rule 10b5-1 trading plan?
The Form 4 indicates the document-level Rule 10b5-1 checkbox was not marked as affirming plan use (aff_10b5_one is false). No footnote language in this data specifies that these trades were executed under a 10b5-1 plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
